Last reviewed · How we verify
Gatifloxacin 0.3% ophthalmic solution
Quinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV.
Quinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV. Used for Bacterial conjunctivitis.
At a glance
| Generic name | Gatifloxacin 0.3% ophthalmic solution |
|---|---|
| Sponsor | Allergan |
| Drug class | Quinolone antibiotic |
| Target | DNA gyrase and topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Gatifloxacin exerts its antibacterial effects by binding to the bacterial enzymes DNA gyrase and topoisomerase IV, thereby inhibiting bacterial DNA replication and transcription.
Approved indications
- Bacterial conjunctivitis
Common side effects
- Dry eye
- Eye irritation
- Headache
Key clinical trials
- Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. (PHASE3)
- Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) (PHASE2)
- Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/Inflammation (PHASE3)
- Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis (PHASE3)
- A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms (PHASE4)
- Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects (PHASE1)
- Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision (NA)
- Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gatifloxacin 0.3% ophthalmic solution CI brief — competitive landscape report
- Gatifloxacin 0.3% ophthalmic solution updates RSS · CI watch RSS
- Allergan portfolio CI